Alpha Blue Ocean Announces the Appointment of Sebastien Bearez as Chief Financial Officer
Alpha Blue Ocean, a family office founded by Pierre Vannineuse, is pleased to announce the appointment of Sebastien Bearez as Chief Financial Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220223005832/en/
Sebastien Bearez CFO Alpha Blue Ocean. (Photo: Alpha Blue Ocean)
Sebastien Bearez takes over, with immediate effect, the administrative and financial management of the family office. He will also be in charge of risk management within the Alpha Blue Ocean Group.
With Master's degrees in computer engineering, business, and two Masters degrees in law (financial law and wealth management), Sebastien is currently completing a thesis with a view to obtaining a doctorate.
Beyond a brilliant academic career, Sebastien Bearez has worked for various large companies in the field of consulting and finance. He began his career at Grant Thornton as an Audit and Management Consultant. After a stint at Deloitte, he joined the BNP Paribas Group as Global CIB Risk Officer.
In 2017, he became Legal Consultant R&D and Financing at F-Iniciativas, a position that confirmed his appetite for and skills in innovation. After having been Secretary General of BJ Invest for the last two years, Sebastien joined the Alpha Blue Ocean teams’ Dubai office.
Amine Nedjai, CEO of Alpha Blue Ocean: “We are very pleased to welcome Sebastien to our team. His background, determination and skills in financial analysis and innovation are all assets that will be highly valuable as we continue to develop and accelerate the business".
Sebastien Bearez, CFO of Alpha Blue Ocean: “It was a very easy decision to join Alpha Blue Ocean. There are many exciting innovation and societal challenges that need to be addressed over the coming months and years and Alpha Blue Ocean is in a good place to address them, particularly with its financing DNA being resolutely turned towards medical innovation and the energies of the future! There will be many exciting projects and I am thrilled to be involved.”
For any additional information or to request an interview with an Alpha Blue Ocean executive, do not hesitate to contact the press service: pr@abo.co
Created in 2017, Alpha Blue Ocean is a pioneer in alternative finance providing innovative financing solutions in Europe, particularly in the medical innovation sector. In 4 years, the Group, founded by Pierre Vannineuse has executed more than €1.5 billion in financial commitments, 60% of which has been in the Health & Innovation segments.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223005832/en/
Contact information
PRESS CONTACTS
Rajae Elantari - +971 58 539 7678 – r.elantari@abo.co
Samuel Botton – 06 84 79 99 61 – sbotton@stepconseil.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press Release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press Release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press Release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom